A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children

Health Technology Assessment

Volumn 15, Issue 45, 2011, Pages

  de Whalley, P ^a   Walker, W ^b   Snape, M D ^a   Oeser, C ^c   Casey, M ^b   Moulsdale, P ^d   Harrill, C ^e   Andrews, N ^f   Hoschler, K ^f   Thompson, B ^a   Jones, C ^a   Chalk, J ^a   Kerridge, S ^a   Tomlinson, R ^e   Heath, P T ^c   Finn, A ^d   Faust, S ^b   Miller, E ^f   Pollard, A J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG TOLERABILITY; FOLLOW UP; HEMAGGLUTINATION; HUMAN; IMMUNOGENICITY; INFANT; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PANDEMIC INFLUENZA; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; UNITED KINGDOM; VIRUS NEUTRALIZATION;

EID: 84856367660     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta15450     Document Type: Article

References (43)

1. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quiñones-Falconi F, Bautista E, et al. Pneumonia and respiratory failure from swine-origin Influenza A (H1N1) in Mexico. N Engl J Med 2009;361:680-9.
2. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, et al. Pandemic potential of a strain of Influenza A (H1N1): early findings. Science 2009;324:1557-61.
3. Donaldson LJ, Rutter PD, Ellis BM, Greaves FEC, Mytton OT, Pebody RG, et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 2009;339:b5213.
4. Chan M. World now at the start of 2009 influenza pandemic. World Health Organisation, 2009. URL: www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_200906 11/en/index.html (accessed 1 August 2011).
5. McLean E, Pebody RG. Epidemiological report of pandemic (H1N1) 2009 in the UK. Health Protection Agency, 2010. URL: www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1284475321350 (accessed 1 August 2011).
6. Health Protection Agency. HPA weekly national influenza report. 2011. URL: www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1287147913271
7. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009;361:1945-52.
8. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010;375:1100-8.
9. Sachedina N, Donaldson L. Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study. Lancet 2010;376:1846-52.
10. Yang Y, Sugimoto JD, Halloran ME, Basta NE, Chao DL, Matrajt L, et al. The transmissibility and control of pandemic influenza A (H1N1) virus. Science 2009;326:729-33.
11. Kuehn BM. CDC names H1N1 vaccine priority groups. JAMA 2009;302:1157-8.
12. Salisbury DM. H1N1 influenza vaccination programme: information materials and vaccine schedule information. Department of Health, 2009. URL: www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolle agueletters/DH_107665 (accessed 1 August 2011).
13. Donaldson L. Extending the H1N1 swine flu vaccination programme 2009/2010. Department of Health, 2009. URL: www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/d igitalasset/dh_108896.pdf (accessed 1 August 2011).
14. Dalton I. A (H1N1) swine flu influenza: phase two of the vaccination programme; children over 6 months and under 5 years. Department of Health, 2009. URL: www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolle agueletters/DH_109826 (accessed 1 August 2011).
15. World Health Organization. Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. 2010. URL: www.who.int/csr/disease/influenza/201002_Recommendation.pdf (accessed 1 August 2011).
16. Watson J, Peabody R. Pandemic influenza vaccines. BMJ 2011;342:d545.
17. B/oil-in-water emulsion-adjuvanted (AS03B) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. Health Technol Assess 2010;14(46):1-130.
18. Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010;340:c2649.
19. European Medicines Agency. Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context. 2007. URL: www.ema.europa.eu/pdfs/human/vwp/26349906enfin.pdf (accessed 1 August 2011).
20. Wright P, Sannella E, Shi J, Zhu Y, Ikizler M, Edwards K. Antibody responses after inactivated influenza vaccine in young children. Pediatr Infect Dis J 2008;27:1004-8.
21. Hardelid P, Andrews N, Hoschler K, Stanford E, Baguelin M, Waight P, et al. Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza AH1N1 2009. Health Technol Assess 2010;14(55):115-92.
22. Russell S, McCahon D, Beare A. A single radial haemolysis technique for the measurement of influenza antibody. J Gen Virol 1975;27:1-10.
23. Potter C, Oxford J. Determinants of immunity to influenza infection in man. Br Med Bull 1979;35:69-75.
24. Wood JM, Levandowski RA. The influenza vaccine licensing process. Vaccine 2003;21:1786-8.
25. Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011;11:91-101.
26. Andrews N, Waight P, Yung C-F, Miller E. Age specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis 2011;203:32-9.
27. Hardelid P, Fleming D, McMenamin J, Andrews N, Robertson C, Sebastian Pillai P, et al. Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009-2010. Eurosurveillance 2011;16(2):pii=19763.
28. Pebody R, Hardelid P, Fleming D, McMenamin J, Andrews N, Robertson C, et al. Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. Eurosurveillance 2011;16(6):pii=19791.
29. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009;27:6291-5.
30. Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D, et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. Pediatrics 2011;127:e1161-8.
31. Meier S, Bel M, L'Huillier A, Crisinel P-A, Combescure C, Kaiser L, et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. Vaccine 2011;29:3548-57.
32. Kilpi T, Nohnyek H. Increased risk of narcolepsy observed among children and adolescents vaccinated with PandemrixR. National Institute for Health and Welfare, 2011. URL: www.thl.fi/en_US/web/en/pressrelease?id=24103 (accessed 1 August 2011).
33. World Health Organization. Reviews on narcolepsy following administration of Pandemrix vaccine. Copenhagen: World Health Organization; 2011.
34. Carlson B, Jansson A, Larsson A, Bucht A, Lorentzen J. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am J Pathol 2000;156:2057-65.
35. Satoh M, Kuroda Y, Yoshida H, Behney KM, Mizutani A, Akaogi J, et al. Induction of lupus autoantibodies by adjuvants. J Autoimmun 2003;21:1-9.
36. Schmidt-Ott R, Schwarz T, Haase R, Sander H, Walther U, Fourneau M, et al. Immunogenicity and reactogenicity of a trivalent influenza split vaccine in previously unvaccinated children aged 6-9 and 10-13 years. Vaccine 2007;26:32-40.
37. Neuzil K, Jackson L, Nelson J, Klimov A, Cox N, Bridges C, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis 2006;194:1032-9.
38. Neuzil K, Dupont W, Wright P, Edwards K. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 2001;20:733-40.
39. Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O'Hagan DT, et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011;29:1812-23.
40. Gonzalez M, Pirez M, Ward E, Dibarboure H, Garcia A, Picolet H. Safety and immunogenicity of a paediatric presentation of an influenza vaccine. Arch Dis Child 2000;83:488-91.
41. Bishop J. Health authorities continue to put seasonal flu vaccine on hold for young children. Australian Government, Department of Health and Ageing, 2010. URL: www.health.gov.au/internet/main/publishing.nsf/Content/97017E09250CF5A1C A257717007FCCF1/$File/dept300410.pdf (accessed 1 August 2011).
42. Bishop J. Seasonal flu vaccination for young children can be resumed. Australian Government, Department of Health and Ageing, 2010. URL: www.health.gov.au/internet/main/publishing.nsf/Content/F8C473DAE9FFF923C A25777000082F2A/$File/dept300710.pdf (accessed 1 August 2011).
43. US Food and Drug Administration. Fluzone vaccine safety. US Department of Health and Human Services, 2011. URL: www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ucm2 40037.htm (accessed 1 August 2011).